BioCryst Pharmaceuticals, Inc.
BCRX
$10.34
$0.505.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 110.86% | -393.60% | 1,805.92% | 153.67% | 15,790.63% |
| Total Depreciation and Amortization | -51.65% | 24.24% | -56.74% | 500.00% | -0.60% |
| Total Amortization of Deferred Charges | 36.24% | -- | -- | -- | -15.63% |
| Total Other Non-Cash Items | -96.12% | 1,679.53% | 45.92% | -14.92% | -1.95% |
| Change in Net Operating Assets | 95.64% | -1,789.21% | 408.54% | -157.64% | 103.83% |
| Cash from Operations | 268.86% | -121.16% | 601.42% | 0.78% | 250.10% |
| Capital Expenditure | 48.14% | 49.75% | 40.33% | -650.84% | -25.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | 100.00% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -149.69% | 389.18% | -632.53% | -50.98% | 7.59% |
| Cash from Investing | 59.00% | -221.78% | -715.15% | -53.40% | 7.50% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -1,569.67% | 99.58% | -223.95% | 20.19% | -14,677.13% |
| Issuance of Common Stock | -67.98% | 2,769.41% | -74.51% | -22.22% | 43.16% |
| Repurchase of Common Stock | -211.04% | 80.22% | -855.73% | 27.48% | 35.90% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 68.05% | -- | -- | -- |
| Cash from Financing | -102.70% | 289.28% | -270.59% | 20.18% | -14,029.30% |
| Foreign Exchange rate Adjustments | 51.39% | 0.00% | 84.62% | -134.44% | 201.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 6,707.34% | 101.45% | -- |
| Net Change in Cash | -120.71% | 1,453.81% | 236.50% | 77.19% | -3,138.71% |